title: [Pelvic posterior exenteration with immediate colo-rectal anastomosis: is it justified and feasible in advanced stage ovarian carcinoma?].
abstract: OBJECTIVE
  The aim of this study is to show that the removal of the rectum is not an obstacle to implement an optimal surgery in advanced epithelial cancer of the ovary.
  
  
  METHODS
  Retrospective study on a population of 44 women with advanced epithelial cancer of the ovary. The surgery was realized between January 95 and July 03, and all surgeries required a posterior exenteration. This treatment was completed by chemotherapy for 36 of them.
  
  
  RESULTS
  The median survival of this population is 36.6 months. 6/44 patients (13.6%) had post-operative complications. The completion of chemotherapy started after an average of 5.2 weeks after surgery. All the assessable patients (43/44) have an anal satisfactory continence.
  
  
  CONCLUSIONS
  The posterior exenteration, when it's necessary, for advanced epithelial cancer of the ovary must not be an obstacle to obtain an optimal surgery. Anal continence is respected and there are no more complications. This surgical act is safe for the management of this pathology without delaying the others therapeutics and allowing a satisfactory quality of life.
authors.affiliation: Service de chirurgie oncologique 2, institut Paoli-Calmettes, 232, boulevard Sainte-Marguerite, BP 156, 13273 Marseille cedex 09, France. buttarellim@marseille.fnclcc.fr
authors.forename: M
authors.initials: M
authors.lastname: Buttarelli
authors.forename: G
authors.initials: G
authors.lastname: Houvenaeghel
authors.forename: L
authors.initials: L
authors.lastname: Lelièvre
authors.forename: J
authors.initials: J
authors.lastname: Jacquemier
authors.forename: J
authors.initials: J
authors.lastname: Guiramand
authors.forename: J-R
authors.initials: JR
authors.lastname: Delpero
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000601:surgery*; D018262:Adenocarcinoma, Clear Cell / Q000473:pathology / Q000601:surgery; D002288:Adenocarcinoma, Mucinous / Q000473:pathology / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000714:Anastomosis, Surgical; D018269:Carcinoma, Endometrioid / Q000473:pathology / Q000601:surgery*; D002296:Carcinosarcoma / Q000473:pathology / Q000601:surgery*; D003106:Colon / Q000601:surgery*; D003125:Colostomy; D018284:Cystadenocarcinoma, Serous / Q000473:pathology / Q000601:surgery; D015653:Cystectomy; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007044:Hysterectomy; D007081:Ileostomy; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D010053:Ovary / Q000473:pathology; D010385:Pelvic Exenteration; D011300:Preoperative Care; D011788:Quality of Life; D012007:Rectum / Q000601:surgery*; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome